Emilien Ezine
Overview
Explore the profile of Emilien Ezine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ezine E, Da Silva A, Idoudi S, Lebbe C, Chretien B, Sassier M, et al.
Therapie
. 2025 Jan;
PMID: 39855945
Importance: The safety profile of a rechallenge with BRAF inhibitors (BRAFi) or a combination of BRAF and MEK inhibitors (MEKi) following an adverse drug reaction (ADR) remains largely unexplored. Objective:...
2.
Ezine E, Lebbe C, Dumaz N
Clin Transl Med
. 2023 Oct;
13(10):e1464.
PMID: 37877351
Background: Although the PI3K/AKT/mTOR pathway is one of the most altered pathways in human tumours, therapies targeting this pathway have shown numerous adverse effects due to positive feedback paradoxically activating...
3.
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Dolladille C, Akroun J, Morice P, Dompmartin A, Ezine E, Sassier M, et al.
Eur Heart J
. 2021 Sep;
42(48):4964-4977.
PMID: 34529770
Aims: The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown. Methods And Results: We systematically reviewed all...
4.
Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen L, Alexandre J, et al.
Am J Hematol
. 2021 May;
96(9):1101-1111.
PMID: 34057232
Chimeric-antigen-receptor T cells directed against CD19 (CAR-T) are emerging hematological therapeutics with scarce data on its overall safety profile spectrum. To determine the clinical features and incidence of adverse-drug reactions...
5.
Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jan;
48(8):2573-2585.
PMID: 33432374
Background: Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma. There is a need for robust biomarkers to identify patients who do not respond. We analysed 14 baseline...
6.
Dolladille C, Font J, Bejan-Angoulvant T, Zaman K, Sassier M, Ezine E, et al.
Arch Cardiovasc Dis
. 2020 May;
113(6-7):420-432.
PMID: 32418884
Background: The risk of cardiovascular adverse events from rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is not fully characterized. Aim: To evaluate the cardiovascular adverse...